TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Genenta Science
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Genenta Science reported positive survival metrics in its TEM-GBM study for glioblastoma patients, with 44% reaching 18-month survival and one patient surviving 39 months after treatment. The company also announced approximately $30 million in cash and short-term investments following a recent direct offering.

Insights
GNTA   positive

The company reported promising clinical trial results with improved patient survival rates compared to historical standards, demonstrated potential in their therapeutic approach, and maintained a strong cash position